Spyre Therapeutics stock
SYRENASDAQSpyre Therapeutics, Inc., HealthcareISIN US00773J2024
48Score 48 out of 100, Weak
Price and trend
86 / 100
Price history
+339% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 35% above it.
Since October 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 65).
The price is 5.6% below its 52-week high. Largest decline in 11 years: 99% (April 2016 to June 2023).
Chart figures for advanced users
- SMA 50$91.15
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$76.32
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)65
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$22.63
- The lowest closing price of the last twelve months.
- Resistance$109.00
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Spyre Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $9.77B, is number 37 of 296 companies in its industry on MEQIRI.
- MEQIRI Score 48 out of 100 (Weak): rank 412 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $1.07B, financial debt $0.Stability 70
Weaknesses
- Loss-makingLoss of $263.86M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$249.32M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 67% a year over the last 12 months.
Its standout strengths are momentum and technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
From 2021 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%. Last 12 months: net −100%. From 2021 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterNo financial debt is reported on the balance sheet.
Earnings
- Next earnings
- 18 Feb 2027in 98 days
- Last reported
- 3 Nov 2026EPS reported −$0.94 (expected −$0.82)below expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 14.7% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$3.12−14.7%
- Revenue
- $88.6K0.0%
- Earnings per share
- −$3.86−7.3%
- Revenue
- $166.67K0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 7 insiders sold, $424.79M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- King-Jones HeidySale
1 Oct 2026, See Remarks
- Shares
- 28,933
- Price
- $91.03
- Value
- $2.63M
- Turtle CameronSale
1 Oct 2026, Chief Executive Officer
- Shares
- 15,000
- Price
- $92.01
- Value
- $1.38M
- Burrows Scott LSale
1 Oct 2026, Chief Financial Officer
- Shares
- 7,500
- Price
- $91.83
- Value
- $688,756
Show 18 more
- Burrows Scott LSale
30 Sept 2026, Chief Financial Officer
- Shares
- 17,500
- Price
- $89.89
- Value
- $1.57M
- King-Jones HeidySale
2 Sept 2026, See Remarks
- Shares
- 400
- Price
- $90.00
- Value
- $36,000
- Burrows Scott LSale
2 Sept 2026, Chief Financial Officer
- Shares
- 18,232
- Price
- $89.35
- Value
- $1.63M
- King-Jones HeidySale
1 Sept 2026, See Remarks
- Shares
- 27,999
- Price
- $87.31
- Value
- $2.44M
- Burrows Scott LSale
1 Sept 2026, Chief Financial Officer
- Shares
- 7,500
- Price
- $87.31
- Value
- $654,792
- Turtle CameronSale
1 Sept 2026, Chief Executive Officer
- Shares
- 15,000
- Price
- $87.29
- Value
- $1.31M
- Albers Jeffrey W.Sale
7 Aug 2026, Board
- Shares
- 23,000
- Price
- $104.53
- Value
- $2.4M
- Burrows Scott LSale
3 Aug 2026, Chief Financial Officer
- Shares
- 7,500
- Price
- $95.57
- Value
- $716,771
- Turtle CameronSale
3 Aug 2026, Chief Executive Officer
- Shares
- 15,000
- Price
- $95.51
- Value
- $1.43M
- Burrows Scott LSale
1 Jul 2026, Chief Financial Officer
- Shares
- 7,500
- Price
- $87.74
- Value
- $658,040
- Sloan SheldonSale
1 Jul 2026, Chief Medical Officer
- Shares
- 8,334
- Price
- $87.70
- Value
- $730,896
- Turtle CameronSale
1 Jul 2026, Chief Executive Officer
- Shares
- 15,000
- Price
- $87.69
- Value
- $1.32M
- Burrows Scott LSale
25 Jun 2026, Chief Financial Officer
- Shares
- 15,000
- Price
- $87.13
- Value
- $1.31M
- Fairmount Funds Management LLCSale
23 Jun 2026, Board
- Shares
- 4,684,781
- Price
- $85.31
- Value
- $399.66M
- Henderson Michael ThomasSale
22 Jun 2026, Board
- Shares
- 20,000
- Price
- $100.00
- Value
- $2M
- Sloan SheldonSale
3 Jun 2026, Chief Medical Officer
- Shares
- 8,333
- Price
- $75.00
- Value
- $624,975
- Turtle CameronSale
1 Jun 2026, Chief Executive Officer
- Shares
- 15,000
- Price
- $70.43
- Value
- $1.06M
- Burrows Scott LSale
1 Jun 2026, Chief Financial Officer
- Shares
- 7,500
- Price
- $71.06
- Value
- $532,937
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Spyre Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 48
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- BioMarin PharmaceuticalBMRN $11.3B50
- VaxcytePCVX $10.8B46
- Akeso9926.HK $10.58B32
- Sichuan Kelun Pharmaceutical002422.SZ $10.43B70
- TG TherapeuticsTGTX $10.07B65
- Genscript Biotech1548.HK $9.96B48
- Haisco Pharmaceutical Group002653.SZ $9.92B68
- Praxis Precision MedicinesPRAX $9.67B42
ETFs that hold Spyre Therapeutics
Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Harbor Health Care UCITS ETF AccW311 | 1.02% | 0.89% | €11.61M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.56% | 0.35% | €1.21B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.28% | 0.30% | €2.17B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.27% | 0.30% | €4.22B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.21% | 0.30% | €185.82M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.09% | 0.43% | €2.48B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.06% | 0.35% | €8.19B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.06% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Apr 2017)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.